The FDA has granted accelerated approval to Modeyso™ (dordaviprone) as the first treatment for recurrent H3 K27M-mutant ...

The FDA has accepted Bristol Myers Squibb’s Priority Review application for Breyanzi® (lisocabtagene maraleucel) as a ...

CLD-201 (SuperNova), a novel stem cell–based oncolytic virus therapy, has received FDA Fast Track designation for soft tissue ...

This weekend, the Pan-Mass Challenge (PMC) unites more than 6,500 riders and 3,500 volunteers for its 46th ride, with the ...

Researchers have identified eIF2A as a key protein that guides melanoma cells during metastasis. Known for its role in aiding ...

A multi-institutional study found that 42% of ovarian cancer patients in clinical remission still harbored minimal residual ...

A novel radioimmunotherapy strategy has shown compelling efficacy in eliminating ovarian cancer stem cells in preclinical models, marking a major advance in efforts to address relapse and resistance ...

The ARANOTE trial showed that adding darolutamide to ADT reduced the risk of progression or death by 46% in metastatic hormone-sensitive prostate cancer, with a safety profile similar to ADT alone. Dr ...